Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review

Abstract T lymphoblastic lymphoma/acute lymphoblastic leukemia (T-LBL/ALL) is a highly aggressive hematologic malignancy, with particularly poor outcomes for refractory/relapsed (R/R) patients. This article reports the efficacy and safety of V-CHG regimen (Venetoclax, cytarabine, homoharringtonine,...

Full description

Saved in:
Bibliographic Details
Main Authors: Mei Zhou, Yuze Yang, Xiaoyan Zhang, Yijie Jiao, Zhenxing Guo
Format: Article
Language:English
Published: Springer 2025-07-01
Series:Discover Oncology
Subjects:
Online Access:https://doi.org/10.1007/s12672-025-03055-4
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849238472699674624
author Mei Zhou
Yuze Yang
Xiaoyan Zhang
Yijie Jiao
Zhenxing Guo
author_facet Mei Zhou
Yuze Yang
Xiaoyan Zhang
Yijie Jiao
Zhenxing Guo
author_sort Mei Zhou
collection DOAJ
description Abstract T lymphoblastic lymphoma/acute lymphoblastic leukemia (T-LBL/ALL) is a highly aggressive hematologic malignancy, with particularly poor outcomes for refractory/relapsed (R/R) patients. This article reports the efficacy and safety of V-CHG regimen (Venetoclax, cytarabine, homoharringtonine, G-CSF) in the treatment of three R/R T-LBL/ALL cases. One 69 years old female patient with T-ALL experienced a twice relapse and achieved morphological complete remission (CR) with one cycle of V-CHG regimen. Another 65 years old female patient with T-LBL progressed to T-ALL after continuous CR for 10 months and failed by two different salvage chemotherapy regimens. She achieved minimal residual disease (MRD) negative CR with a third-line treatment based on V-CHG regimen. The third T-ALL patient was a 26 years old male who resistant to VDCP induction regimen and achieved morphological CR with one cycle of V-CHG regimen, and obtained MRD negative CR after second cycle treatment. All the three patients were well tolerated to the V-CHG regimen. The results of this study indicate that the V-CHG regimen is effective and safe for R/R T-LBL/ALL, warranting further application in the future.
format Article
id doaj-art-9af33304428a434c88009608e3d8229d
institution Kabale University
issn 2730-6011
language English
publishDate 2025-07-01
publisher Springer
record_format Article
series Discover Oncology
spelling doaj-art-9af33304428a434c88009608e3d8229d2025-08-20T04:01:35ZengSpringerDiscover Oncology2730-60112025-07-011611810.1007/s12672-025-03055-4Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature reviewMei Zhou0Yuze Yang1Xiaoyan Zhang2Yijie Jiao3Zhenxing Guo4Department of Hematology/Oncology, First Hospital of Tsinghua University, School of Medicine, Tsinghua UniversityDepartment of Hematology/Oncology, First Hospital of Tsinghua University, School of Medicine, Tsinghua UniversityDepartment of Hematology/Oncology, First Hospital of Tsinghua University, School of Medicine, Tsinghua UniversityDepartment of Hematology/Oncology, First Hospital of Tsinghua University, School of Medicine, Tsinghua UniversityDepartment of Hematology/Oncology, First Hospital of Tsinghua University, School of Medicine, Tsinghua UniversityAbstract T lymphoblastic lymphoma/acute lymphoblastic leukemia (T-LBL/ALL) is a highly aggressive hematologic malignancy, with particularly poor outcomes for refractory/relapsed (R/R) patients. This article reports the efficacy and safety of V-CHG regimen (Venetoclax, cytarabine, homoharringtonine, G-CSF) in the treatment of three R/R T-LBL/ALL cases. One 69 years old female patient with T-ALL experienced a twice relapse and achieved morphological complete remission (CR) with one cycle of V-CHG regimen. Another 65 years old female patient with T-LBL progressed to T-ALL after continuous CR for 10 months and failed by two different salvage chemotherapy regimens. She achieved minimal residual disease (MRD) negative CR with a third-line treatment based on V-CHG regimen. The third T-ALL patient was a 26 years old male who resistant to VDCP induction regimen and achieved morphological CR with one cycle of V-CHG regimen, and obtained MRD negative CR after second cycle treatment. All the three patients were well tolerated to the V-CHG regimen. The results of this study indicate that the V-CHG regimen is effective and safe for R/R T-LBL/ALL, warranting further application in the future.https://doi.org/10.1007/s12672-025-03055-4T lymphoblastic lymphoma/T acute lymphoblastic leukemiaVenetoclaxHomoharringtonineCHG regimenRefractory/relapsed
spellingShingle Mei Zhou
Yuze Yang
Xiaoyan Zhang
Yijie Jiao
Zhenxing Guo
Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review
Discover Oncology
T lymphoblastic lymphoma/T acute lymphoblastic leukemia
Venetoclax
Homoharringtonine
CHG regimen
Refractory/relapsed
title Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review
title_full Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review
title_fullStr Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review
title_full_unstemmed Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review
title_short Combination of venetoclax with CHG regimen in refractory/relapsed T-lymphoblastic lymphoma/acute lymphoblastic leukemia: a case series and literature review
title_sort combination of venetoclax with chg regimen in refractory relapsed t lymphoblastic lymphoma acute lymphoblastic leukemia a case series and literature review
topic T lymphoblastic lymphoma/T acute lymphoblastic leukemia
Venetoclax
Homoharringtonine
CHG regimen
Refractory/relapsed
url https://doi.org/10.1007/s12672-025-03055-4
work_keys_str_mv AT meizhou combinationofvenetoclaxwithchgregimeninrefractoryrelapsedtlymphoblasticlymphomaacutelymphoblasticleukemiaacaseseriesandliteraturereview
AT yuzeyang combinationofvenetoclaxwithchgregimeninrefractoryrelapsedtlymphoblasticlymphomaacutelymphoblasticleukemiaacaseseriesandliteraturereview
AT xiaoyanzhang combinationofvenetoclaxwithchgregimeninrefractoryrelapsedtlymphoblasticlymphomaacutelymphoblasticleukemiaacaseseriesandliteraturereview
AT yijiejiao combinationofvenetoclaxwithchgregimeninrefractoryrelapsedtlymphoblasticlymphomaacutelymphoblasticleukemiaacaseseriesandliteraturereview
AT zhenxingguo combinationofvenetoclaxwithchgregimeninrefractoryrelapsedtlymphoblasticlymphomaacutelymphoblasticleukemiaacaseseriesandliteraturereview